SOPHiA Genetics Partners with AstraZeneca to Expand Testing

SOPHiA Genetics has announced a partnership with AstraZeneca to enhance liquid biopsy testing deployment globally. The collaboration aims to maximize benefits for labs and patients, a move that could positively influence stock performance amidst rising share prices.

Date: 10-09-2024

AI Rating: 7

SOPHiA Genetics SA (SOPH) has entered into a partnership with AstraZeneca (AZN) aimed at expanding the deployment of liquid biopsy testing. This partnership involves the extension of the liquid biopsy testing, MSK-ACCESS — powered by SOPHiA DDM — to 20 locations worldwide within the coming year.

The collaboration seeks to investigate how liquid biopsy testing may complement traditional solid tissue testing, potentially benefiting laboratories and patients alike. This is a significant strategic move that could position both companies more favorably in the biopharmaceutical market, especially as the demand for innovative diagnostic solutions increases.

As of the latest information, SOPHiA Genetics's stock is trading at $3.79, showing an increase of 2.84 percent on Nasdaq. This uptick in stock price may reflect positive investor sentiment following the announcement of this partnership.

Stocks: SOPH AZN